Last updated March 15, 2022

Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus

Recommendations

ACP recommends that clinicians prescribe metformin to patients with type 2 diabetes when pharmacologic therapy is needed to improve glycemic control. (Moderate, Strong)
317067

ACP recommends that clinicians consider adding either a sulfonylurea, a thiazolidinedione, an SGLT-2 inhibitor, or a DPP-4 inhibitor to metformin to improve glycemic control when a second oral therapy is considered. (Moderate, Weak)
ACP recommends that clinicians and patients select among medications after discussing benefits, adverse effects, and costs.
317067

Recommendation Grading

Overview

Title

Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus

Authoring Organization

Endorsing Organization

Publication Month/Year

February 21, 2017

Document Type

Guideline

External Publication Status

Published

Country of Publication

US

Inclusion Criteria

Female, Male, Adult, Older adult

Health Care Settings

Ambulatory, Hospital

Intended Users

Dietician nutritionist, diabetes educator, nurse, nurse practitioner, physician, physician assistant

Scope

Management, Treatment

Diseases/Conditions (MeSH)

D003924 - Diabetes Mellitus, Type 2

Keywords

type 2 diabetes mellitus, hyperglycemia, diabetic retinopathy, HbA1c, oral drug therapy

Methodology

Number of Source Documents
140
Literature Search Start Date
April 1, 2009
Literature Search End Date
December 1, 2015